Joined Today: 0

ALNY Alnylam Pharmaceuticals, Stock Message Board

All Messages

ALNY Message Board Home | Join The ALNY Group |

#90: Alnylam to Webcast Presentation at UBS 2008 Global Life Sciences Conference
TheMachine	September 19, 2008 12:29:02 PM
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the UBS 2008 Global... view message ignore post recommend post

#89: Alnylam Initiates Phase II Trial to Evaluate Safety and Tolerability of ALN-RSV01 in Adult Lung Transplant Patients Naturally Infected with Respiratory Syncytial Virus (RSV) Infection
NewsBot	April 13, 2008 03:49:39 PM
Alnylam Initiates Phase II Trial to Evaluate Safety and Tolerability of ALN-RSV01 in Adult Lung Transplant Patients Naturally Infected with Respiratory Syncytial Virus (RSV) Infection ... view message ignore post recommend post

#88: Alnylam to Webcast Presentation at the 19th Annual Piper Jaffray Health Care Conference with Focus on Intellectual Property
FastFun	November 26, 2007 07:16:23 AM
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview with a focus on its intellectual property estate... view message ignore post recommend post

#87: Regulus Therapeutics Announces Allowance of Key Patent on microRNA Therapeutics for the Treatment of Hepatitis C Virus Infection
FastFun	November 26, 2007 07:13:54 AM
New Patent Strengthens Regulus’ Leadership in microRNA Therapeutics Regulus Therapeutics, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals,... view message ignore post recommend post

#86: ALNY News Alnylam Grants Bio-Rad License to Kreutzer-Limmer Patents for the RNA Interference (RNAi) Research Products Market
NewsBot	March 29, 2007 05:00:00 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has granted Bio-Rad a non-exclusive license... view message ignore post recommend post

#85: ALNY News Alnylam to Webcast Presentation at 2007 Future Leaders in the Biotech Industry Conference
NewsBot	March 23, 2007 05:00:00 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at... view message ignore post recommend post

#84: ALNY News Alnylam and Stanford University Scientists Discover New Role for microRNAs (miRNAs) in T Cell Biology and Immunity
NewsBot	March 22, 2007 12:16:00 PM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today publication of a study in the journal Cell by... view message ignore post recommend post

#83: ALNY News Alnylam to Webcast Presentation at the Lehman Brothers Tenth Annual Global Healthcare Conference
NewsBot	March 13, 2007 01:00:00 PM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at... view message ignore post recommend post

#82: ALNY News Alnylam to Webcast at the Cowen and Company 27th Annual Health Care Conference
NewsBot	March 7, 2007 02:01:00 PM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at... view message ignore post recommend post

#81: ALNY News Alnylam and Isis Announce Allowance of First U.S. Patent Covering Human microRNAs
NewsBot	March 1, 2007 04:00:00 AM
CAMBRIDGE, Mass. & CARLSBAD, Calif.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that the United States Patent... view message ignore post recommend post

#80: ALNY News Alnylam Scientist Awarded Two Industry Honors
NewsBot	February 28, 2007 05:00:00 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that Dr. Rachel Meyers, Director of Research at... view message ignore post recommend post

#79: ALNY News Alnylam and Inex Form Strategic Technology Alliance to Discover and Develop RNAi Therapeutics with Lipid-Based Delivery Formulations
NewsBot	January 9, 2007 05:00:00 AM
CAMBRIDGE, Mass. & VANCOUVER, British Columbia--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, and Inex Pharmaceuticals Corporation... view message ignore post recommend post

#78: ALNY News Alnylam Announces Key Product and Business Goals for 2007
NewsBot	January 8, 2007 05:01:00 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today its key product and business goals for 2007,... view message ignore post recommend post

#77: ALNY News Alnylam to Webcast Presentation at the 25th Annual JPMorgan Healthcare Conference
NewsBot	January 3, 2007 04:30:00 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview... view message ignore post recommend post

#76: ALNY News Alnylam Announces Closing of Common Stock Offering
NewsBot	December 15, 2006 01:01:00 PM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today the closing of its public offering of 4,700,000 shares of common stock. Net proceeds to... view message ignore post recommend post

Group Home | Login if you want to post a message